<DOC>
	<DOC>NCT00780000</DOC>
	<brief_summary>The purpose of this study is to determine the anti-tumor activity (via objective response rate) of alvespimycin in patients with breast cancer who have not previously received trastuzumab (except as adjuvant therapy).</brief_summary>
	<brief_title>Clinical Trial of Intravenous Alvespimycin in Patients With Her2 Positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>KPS performance status of &gt;= 80% ("normal activity with effort") Metastatic breast cancer with Her2 amplification by FISH or 3+ Her2 overexpression by immunohistochemistry ("IHC") Must have received no more than one prior cytotoxic chemotherapy regimen in the metastatic setting Measurable disease by RECIST Criteria Received prior lapatinib, an investigational ErbB2 and/or an investigational EGFR dual tyrosine kinase inhibitors Administration of any other chemotherapy, biological, immunotherapy or investigational agent within 14 days prior to receipt of study medication Pregnant or breastfeeding women. Known CNS metastases, unless treated and without clinically significant neurological deficits Moderately severe dry eye Congestive heart failure, or a left ventricular ejection fraction Myocardial infarction or active ischemic heart disease within 12 months prior to study drug administration Previous malignancies unless free of recurrence for at least 5 years</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>